Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
9 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Palvella Therapeutics, Inc.’s names, not what it holds today.
Patents granted
9
9 utility, 1976 to Dec 31, 2025
Granted in 2025
2
Against none in 2024 and 2 in 2023
Applications published
13
2 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
PALVELLA THERAPEUTICS, INC. its own name
US, as the owner printed on each patent
11 publishedPALVELLA THERAPEUTICS, INC. its own name
named as the applicant on its applications, in US
2 publishedNames not counted (4)
PIERIS PHARMACEUTICALS, INC.
Most of its patents print DE; this name counts in US. 38 granted and 19 published under it are not counted.
PIERIS PHARMACEUTICALS, INC.
Most of its patents print DE; this name counts in US. 0 granted and 45 published under it are not counted.
Marika Inc.
Most of its patents print AU; this name counts in US. 0 granted and 1 published under it are not counted.
Marika Inc.
Most of its patents print AU; this name counts in US. 0 granted and 1 published under it are not counted.
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Jun 17, 2025 | 12,329,748 | Anhydrous compositions of mTOR inhibitors and methods of use | Pharmaceuticals | PALVELLA THERAPEUTICS, INC. |
| Apr 8, 2025 | 12,268,673 | Anhydrous compositions of mTOR inhibitors and methods of use | Pharmaceuticals | PALVELLA THERAPEUTICS, INC. |
| Jun 20, 2023 | 11,679,101 | Anhydrous compositions of mTOR inhibitors and methods of use | Pharmaceuticals | PALVELLA THERAPEUTICS, INC. |
| Apr 4, 2023 | 11,617,742 | Methods of treating keratin hyperproliferation disorders using mTOR inhibitors | Pharmaceuticals | PALVELLA THERAPEUTICS, INC. |
| Oct 5, 2021 | 11,135,204 | Anhydrous compositions of mTOR inhibitors and methods of use | Pharmaceuticals | PALVELLA THERAPEUTICS, INC. |
| May 11, 2021 | 11,000,513 | Anhydrous compositions of mTOR inhibitors and methods of use | Pharmaceuticals | PALVELLA THERAPEUTICS, INC. |
| Jul 28, 2020 | 10,722,499 | Anyhydrous compositions of mTOR inhibitors and methods of use | Pharmaceuticals | PALVELLA THERAPEUTICS, INC. |
| Jan 8, 2019 | 10,172,789 | Compositions for transdermal delivery of mTOR inhibitors | Pharmaceuticals | PALVELLA THERAPEUTICS, INC. |
| Jan 2, 2018 | 9,855,252 | Methods of treating keratin hyperproliferation disorders using mTOR inhibitors | Pharmaceuticals | PALVELLA THERAPEUTICS, INC. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Jul 17, 2025 | 2025/0228825 | COMPOSITIONS OF RAPAMYCIN AND THEIR USE IN THE TREATMENT OF MICROCYSTIC LYMPHATIC MALFORMATION | Pharmaceuticals | PALVELLA THERAPEUTICS, INC. |
| Jul 3, 2025 | 2025/0213537 | ANHYDROUS COMPOSITIONS OF mTOR INHIBITORS AND METHODS OF USE | Pharmaceuticals | PALVELLA THERAPEUTICS, INC. |
| Dec 5, 2024 | 2024/0398766 | ANHYDROUS COMPOSITIONS OF mTOR INHIBITORS AND METHODS OF USE | Pharmaceuticals | PALVELLA THERAPEUTICS, INC. |
| Sep 5, 2024 | 2024/0293378 | METHODS AND COMPOSITIONS FOR TREATING GORLIN SYNDROME | Pharmaceuticals | PALVELLA THERAPEUTICS, INC. |
| Aug 24, 2023 | 2023/0263781 | ANHYDROUS COMPOSITIONS OF mTOR INHIBITORS AND METHODS OF USE | Pharmaceuticals | PALVELLA THERAPEUTICS, INC. · patent 12,329,748 granted from it |
| Apr 13, 2023 | 2023/0113775 | ANHYDROUS COMPOSITIONS OF EGFR INHIBITORS AND METHODS OF USE | Pharmaceuticals | PALVELLA THERAPEUTICS, INC. |
| Jan 20, 2022 | 2022/0016089 | ANHYDROUS COMPOSITIONS OF mTOR INHIBITORS AND METHODS OF USE | Pharmaceuticals | PALVELLA THERAPEUTICS, INC. · patent 12,268,673 granted from it |
| Aug 12, 2021 | 2021/0244713 | ANHYDROUS COMPOSITIONS OF mTOR INHIBITORS AND METHODS OF USE | Pharmaceuticals | PALVELLA THERAPEUTICS, INC. · patent 11,679,101 granted from it |
| Dec 10, 2020 | 2020/0383956 | METHODS OF TREATING KERATIN HYPERPROLIFERATION DISORDERS USING mTOR INHIBITORS | Pharmaceuticals | PALVELLA THERAPEUTICS, INC. · patent 11,617,742 granted from it |
| Oct 8, 2020 | 2020/0316034 | ANHYDROUS COMPOSITIONS OF mTOR INHIBITORS AND METHODS OF USE | Pharmaceuticals | PALVELLA THERAPEUTICS, INC. · patent 11,135,204 granted from it |
What it applied for, 2024 to 2025: Pharmaceuticals 4.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.